Outcome of Board Meeting

Pat Growth 25pctExceptional ItemResults View source PDF Explain this filing

SHALBY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹170.00

prior close

₹176.46

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-1.1% vs market

Hospital peers, median of 23sector-1.4%-0.4% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-3.7

15m

-3.4

30m

-3.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-0.6-1.1-1.4-0.4

Next day

-0.6-1.7+1.2-2.1+1.6

+4.1-0.7+4.7-1.7+5.7

+3.0-0.4+3.5-0.6+3.6

+2.5+0.4+2.0-0.3+2.8

+2.9+0.4+2.5+0.2+2.7

+0.1+0.3-0.2+0.8-0.7

15d

+0.0+5.5-5.5+0.4-0.4

+0.6+4.6-4.0+0.2+0.4

-4.1+5.3-9.4+2.3-6.4

-7.9+11.6-19.4+2.6-10.5

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shalby Limited reported audited standalone FY2026 revenue of ₹8,985.58 million (up 3.4% YoY) and PAT of ₹1,129.10 million (up 34.8% YoY) with EPS of ₹10.50. Consolidated revenue stood at ₹11,414.29 million with PAT of ₹346.87 million, significantly improved from ₹19.20 million in FY25. The auditors issued an unmodified (clean) opinion on the results. The Board did not recommend any dividend for FY2025-26. One-time tax impact of ₹340.16 million was recognized due to adoption of new tax regime under Section 115BAA, along with MAT credit write-off of ₹42.36 million. An exceptional item of ₹6.96 million was recorded as impairment of investment in subsidiary Yogeshwar Healthcare Limited.

Likely market impact

Strong standalone profitability with 34.8% PAT growth is positive, though the wide gap between standalone (PAT ₹1,129M) and consolidated PAT (₹347M) highlights significant losses in subsidiaries weighing on group performance. No dividend may disappoint income-focused investors.